课题基金 / 基金详情

FY20. TO3. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. NIDA REF. NO. N01DA-19-8947. PERIOD OF PERFORMANCE: 09/01/2020 TO 02/28/2022.

FY20. TO3. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. NIDA REF. NO. N01DA-19-8947. PERIOD OF PERFORMANCE: 09/01/2020 TO 02/28/2022.
2020 财年。
批准号:
10286222
负责人:
DAVID MALLOY
金额:
$30.17万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-20 至 2024-09-19

项目摘要

项目成果

DAVID MALLOY的其他基金

相似基金

相关文献

中文摘要
翻译
承包商应作为药代动力学资源,支持药物开发的药代动力学(PK)和药效学(PD)方面。承包商将为临床药理学/药代动力学研究提供支持,包括相互作用研究。承包商应准备研究方案,监测临床研究以确保符合相关的食品和药物管理局(FDA)规定,管理和处理临床和药代动力学数据,进行PK、PD和统计分析,并准备研究报告。数据/报告将提交给FDA,以支持INDS(研究新药)和NDAS(新药申请)。
英文摘要
The Contractor shall serve as a pharmacokinetic resource in support of the pharmacokinetic (PK) and pharmacodynamics (PD) aspects of the medications development. The contractor will provide support to clinical pharmacology/pharmacokinetic studies including interaction studies. The Contractor shall prepare study protocols, monitor clinical studies to assure that pertinent Food and Drug Administration(FDA) regulations are met, manage and process clinical and pharmacokinetic data, conduct PK, PD, and statistical analyses, and prepare study reports. The data/reports will be submitted to the FDA in support of INDs (Investigational New Drugs) and NDAs (New Drug Applications).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical and Translational Vaccine Development Support for HIV and Other Candidate Agents: Scientific, Quality and Regulatory Support Services
Preclinical and Translational Vaccine Development Support for HIV and Other Candidate Agents: Scientific, Quality and Regulatory Support Services
CANCER PREVENTION CLINICAL TRIALS AUDITING AND INFORMATICS SUPPORT
"IGF::OT::IGF" CANCER PREVENTION CLINICAL TRIALS AUDITING AND INFORMATICS SUPPORT
海外基金